At the JP Morgan Annual Healthcare Conference in San Francisco, Alnylam Pharmaeuticals’ CEO John Maraganore detailed the steady development of the clinical indications for their RNAi technology and announced Phase II clinical trials of ALN-RSV01 for human Respiratory Syncytial Virus (RSV) infection, based on the microRNA silencing technology.
Major developments include usage of the RNAi silencing into Hypercholesterolemia, Liver Cancer and Huntington’s Disease, the latter being developed in partnership with Medtronic.
Alnylam claims possession of the majority of exclusive patents on RNAi technology and continuing successes in partnership building. After a historical deal on a non-exclusive plateform alliance with Roche in July 2007, with an upfront cash payment of $ 331 millions, and a product alliance with Medtronic, Alnylam is looking at extending its RNAi technology and receiving its first POC in Q1 of this year.
Alnylam (NASDAQ:ALNY) was up 4.35% today in after hours trading, reaching a Market Cap of $1.25 billion. Alnylam breakthrough technology and strong product portfolio make it certainly a company to be kept on the radar screen in months and years to come.
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must be logged in to post a comment.